Albumin binding as a general strategy for improving the pharmacokinetics of proteins. - Wikidata - awgldk - TriplyDB

Albumin binding as a general strategy for improving the pharmacokinetics of proteins.

Albumin binding as a general strategy for improving the pharmacokinetics of proteins.

http://www.wikidata.org/entity/Q44209151

about

A novel, non-immunogenic Fyn SH3-derived binding protein with tumor vascular targeting properties Protease-resistant peptide design-empowering nature's fragile warriors against HIV Treatment of type 2 diabetes, lifestyle, GLP1 agonists and DPP4 inhibitors Unraveling the Interaction between FcRn and Albumin: Opportunities for Design of Albumin-Based Therapeutics Fusion to a highly stable consensus albumin binding domain allows for tunable pharmacokinetics The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy Amyloid-β peptide-specific DARPins as a novel class of potential therapeutics for Alzheimer disease Anticalins: the lipocalin family as a novel protein scaffold for the development of next-generation immunotherapies.Site-specific fatty acid-conjugation to prolong protein half-life in vivo Nanobodies as novel agents for cancer therapy.Engineering of a femtomolar affinity binding protein to human serum albumin.Phage display of random peptide libraries: applications, limits, and potential.Combinatorial peptide libraries: mining for cell-binding peptides.Diverse range of small peptides associated with high-density lipoprotein.Synthetic antibodies as therapeutics.One-step purification of a fusion protein of glucagon-like peptide-1 and human serum albumin expressed in pichia pastoris by an immunomagnetic separation technique.Development, characterization, and evaluation of a fusion protein of a novel glucagon-like peptide-1 (GLP-1) analog and human serum albumin in Pichia pastoris.Serum S100A6 concentration predicts peritoneal tumor burden in mice with epithelial ovarian cancer and is associated with advanced stage in patients.Serum albumin-bound proteomic signature for early detection and staging of hepatocarcinoma: sample variability and data classification.An albumin-based tumor-targeted oxaliplatin prodrug with distinctly improved anticancer activity in vivo.Effect of antigen turnover rate and expression level on antibody penetration into tumor spheroids.Identification and characterization of Nanobodies targeting the EphA4 receptor.The benefits and challenges associated with the use of drug delivery systems in cancer therapy Unraveling the mysteries of serum albumin-more than just a serum protein.Conjugation to albumin-binding molecule tags as a strategy to improve both efficacy and pharmacokinetic properties of the complement inhibitor compstatin Monovalency unleashes the full therapeutic potential of the DN-30 anti-Met antibody Polycyclic peptide therapeutics.Chemically modified antibodies as diagnostic imaging agents Extending half-life by indirect targeting of the neonatal Fc receptor (FcRn) using a minimal albumin binding domain.Improving the pharmacokinetic properties of biologics by fusion to an anti-HSA shark VNAR domain Development and characterization of small bispecific albumin-binding domains with high affinity for ErbB3.Engineered antibody variable and constant domains as therapeutic candidates.Generation and characterization of small single domain antibodies inhibiting human tumor necrosis factor receptor 1.Novel exenatide analogs with peptidic albumin binding domains: potent anti-diabetic agents with extended duration of action Challenges and opportunities with glycogen synthase kinase-3 inhibitors for insulin resistance and Type 2 diabetes treatment.Fusion of a short peptide that binds immunoglobulin G to a recombinant protein substantially increases its plasma half-life in mice Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention.Biodistribution and tumor imaging of an anti-CEA single-chain antibody-albumin fusion protein.Chemokine-Releasing Nanoparticles for Manipulation of Lymph Node Microenvironment Genetically engineered humanized mouse models for preclinical antibody studies.

P2860

Q24320137-7A5B1FEA-31A6-451F-B1AF-8601CBBD7E97 Q27010058-33D3DFAD-7FC4-4067-8F61-2CDE48BEB596 Q27021870-D7251095-D344-46E2-A851-09E967775AF7 Q27027238-CAD63346-BC0E-4D7F-B5AE-DEF7A182EC26 Q27701821-EABC41F5-9C87-4D77-83A7-9FC075594D1A Q28257521-433846EE-D0BC-49D3-9F01-E314CCCD3611 Q28655482-7E70760D-2996-4305-8B09-592DB4B9E5CF Q30157932-EB1F7094-FBE1-4B50-9A2F-2FB43ACB70A7 Q30398229-C3B344AC-0610-45F8-BD6D-47873FEE7F70 Q30778309-121C9C07-910A-41AF-B6F1-109CB8704973 Q30844011-8097E0FD-F422-4C47-AB11-95C168099A0C Q31039269-9419EF49-1E6F-4662-A547-8D728C2794C5 Q31144876-875EF252-2DE4-49A6-B6EB-3347A2A78BA4 Q33230587-3EF0CF1A-ADB6-4574-BE28-3DB8EE210E29 Q33265617-0A45DB60-33FE-4C05-9787-4152D390AF8C Q33305182-22D48386-8CBB-4873-B4AD-0F1806482ED0 Q33415965-A75F1A81-CC28-4A5C-8F43-2E997676099D Q33514817-18713F69-4842-4CE1-AD14-DDC3C027C473 Q33590076-AC013808-911F-4D0A-AD3E-4C18EEC0ED2E Q33615268-001F5DA9-8D43-4BD5-B7D0-A5C29CBD0D32 Q33698791-5A26E2B4-4D39-4A9D-A41A-E7C5E9D57684 Q33882055-6B162876-C20F-4675-B2BB-832B50EC4EFB Q33965271-AD816306-6859-4E77-BACA-663151A80CE7 Q34030577-09B8507F-A670-4467-A775-8D918F6B1A9C Q34254555-DDBE4172-659B-4FDA-9FC2-76CFDC9E8AFF Q34285473-9CF68C1A-373F-47D5-9D6B-3BC67ED010B6 Q34324717-3D9C1FCB-291E-4BA5-A97B-7BBADE601640 Q34441433-567534CF-5719-4BB2-AC5C-3BE2B4A600F4 Q34568391-ABB8F27C-451D-4564-B18D-E1EBA4FA8730 Q34724092-940A8F36-33B7-4FDB-A101-6F8BE83F2644 Q34752052-47AF70C2-EC4A-45D3-84AF-644D92B7A9A8 Q35044156-936A4F68-6099-481A-9B6E-B98DF19467B8 Q35080243-554211C5-4549-403C-AC3C-33B40C26CFC0 Q35087618-BAFDBC6F-FC29-47E2-B51D-1EC3E346FE64 Q35207622-076A5E81-2328-4201-9751-7CF7D353C892 Q35212305-7B4E429A-C8CE-4A34-A412-880A490FBA21 Q35236103-EA66321D-F995-4023-A0FA-12D98A97EC2E Q35369090-404FADA6-3818-40D4-8C24-27DB46C36910 Q35383102-E0BDB876-DB95-4321-97C4-44DF81748259 Q35552397-C44E81A1-ED90-4A6F-9BD3-2DF64BE2B93B

P2860

Albumin binding as a general strategy for improving the pharmacokinetics of proteins.

http://www.wikidata.org/entity/Q44209151

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue

2002年學術文章

@zh-hant

name

Albumin binding as a general strategy for improving the pharmacokinetics of proteins.

@en

Albumin binding as a general strategy for improving the pharmacokinetics of proteins.

@nl

type

label

Albumin binding as a general strategy for improving the pharmacokinetics of proteins.

@en

Albumin binding as a general strategy for improving the pharmacokinetics of proteins.

@nl

prefLabel

Albumin binding as a general strategy for improving the pharmacokinetics of proteins.

@en

Albumin binding as a general strategy for improving the pharmacokinetics of proteins.

@nl

P1433

Q44209151-6317751A-C66E-4D0C-89E3-BE2668C95298

P1476

Q44209151-52D1E20F-D366-4FB3-8202-440B3CB1691B

P2093

Q44209151-237436A0-EF64-4977-B377-B0FE4A393CA5

Q44209151-26827627-C96E-4E6C-AEA3-31F4DF71E0E6

Q44209151-456B5010-017C-4CF7-9758-737B8504ADA3

Q44209151-70161B77-CE58-47F5-B804-DA5481BC12DC

Q44209151-CDFAA959-6F13-4032-B474-28575C37AD0C

Q44209151-D34E884E-7D3B-43D2-B761-8A3DB2439C73

Q44209151-FB2AE504-69AD-4E20-8130-47773B2ABE8E

P304

Q44209151-D0F8DDA6-CE33-4E8D-B855-ACD19955C52D

P31

Q44209151-CAF0B7A5-5137-48BF-96D1-31467CF47E3B

P356

Q44209151-6413E28C-B2EA-4340-B142-F096280334D2

P407

Q44209151-7BCFE8BF-537F-4E1A-BA50-37A2B44DA6C8

P433

Q44209151-93EDA18A-CFDE-416A-9758-5B8CFD47F76F

P478

Q44209151-FE5BCB5C-0379-4249-9300-C23F71B7FE39

P577

Q44209151-7FBCE8C7-3E08-45B6-9919-4F8BCB06AAA6

P5875

Q44209151-94027958-5A91-4AA4-8492-60F3F59140FB

P698

Q44209151-3E2767D9-4E39-4C4E-B029-D609582C7631

P356

P1433

Journal of Biological Chemistry

P1476

Albumin binding as a general strategy for improving the pharmacokinetics of proteins.

@en

P2093

Dan Combs

http://www.w3.org/2001/XMLSchema#string

Daniel Kirchhofer

http://www.w3.org/2001/XMLSchema#string

Lisa A Damico

http://www.w3.org/2001/XMLSchema#string

Mark S Dennis

http://www.w3.org/2001/XMLSchema#string

Min Zhang

http://www.w3.org/2001/XMLSchema#string

Miryam Kadkhodayan

http://www.w3.org/2001/XMLSchema#string

Y Gloria Meng

http://www.w3.org/2001/XMLSchema#string

P304

35035-35043

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1074/JBC.M205854200

http://www.w3.org/2001/XMLSchema#string

P407

P433

38

http://www.w3.org/2001/XMLSchema#string

P478

277

http://www.w3.org/2001/XMLSchema#string

P577

2002-07-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11260152

http://www.w3.org/2001/XMLSchema#string

P698

12119302

http://www.w3.org/2001/XMLSchema#string